Antibody-drug Combo Shows Early Promise in Targeting Cancers, Company Says

Antibody-drug Combo Shows Early Promise in Targeting Cancers, Company Says
0
(0)

BrickBio’s antibody-drug conjugate BRKB-28 showed preclinical effectiveness in eradicating breast cancer cells while leaving healthy cells unharmed, the company announced.

BRKB-28 combines an antibody against a cancer protein with a toxic payload, using a linker molecule that connects the two. Once bound to its target, BRKB-28 releases its toxic compound into cancer cells, triggering their death.

Designed with BrickBio’s bioconjugation platform, BRKB-28, which is also being developed for gastric cancer, showed a better performance than leading breast and gastric cancer biologics, which were reported to kill a significant number of healthy cells.

BrickBio states that its platform enables the custom tailoring of any protein, including modifying a protein at any of its sites. These changes can boost the efficacy of protein-based therapeutics, like antibody-drug conjugates or bispecific antibodies (one that can simultaneously bind to two different types of target proteins), by increasing their efficacy and half-life (the time required to reduce the amount of a compound by half, and an indicator of how long its benefits last), while lowering the dose needed and the potential for toxicity.

“It is very promising to see the facile integration of our unique bioconjugation platform into any protein scaffold, as validated with our BRKB-28 candidate,” James Italia, vice president of commercial development at BrickBio, said in a press release.

“Our team is able to quickly generate and screen candidates with a variety of scaffolds, linkers, and payloads with exquisite control over their biophysical characteristics. We are already witnessing the benefit of the BrickBio advantage and look forward to future candidates in our other internal programs,” Italia added.

BrickBio’s platform has allowed the company to expand its therapeutic programs, which now include Antibody-drug conjugates,  Novel Bispecific Antibody Conjugates, and Novel Scaffolds.

“The robustness and flexibility of the BrickBio platform has enabled the company to progress at a much faster rate than initially forecasted, in terms of developing novel antibody drug conjugates, protein therapeutics, and novel bispecific antibody conjugates,” said John Boyce, co-founder, chairman, president and CEO of BrickBio.

“We are not only excited about our first pre-clinical candidate for breast and gastric cancer, but also about the continued work with our pharmaceutical partners to rapidly expand the pipeline across a number of indications,” Boyce, who is also the co-founder of Tiger Gene, a Boston-based venture capital firm that invests in early stage technologies.

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 0
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • Enhertu conditional approval U.K.
  • ARX788 on fast track
  • Tukysa, EU approval
  • cancer treatment early study

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?